The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at American Society of Nephrology Kidney Week 2025 November 5–9.

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the ...

Pregnancy increases the risk of flare in patients with SLE and is associated with excess fetal morbidity and mortality.1 The ...

An estimated 50% of patients with SLE will develop lupus nephritis in their lifetime, with people of African descent more ...

Reports suggest that, internally, the Food and Drug Administration is facing a crisis of confidence. Kennedy's reign has been ...

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

Q3 2025 Earnings Call Transcript November 4, 2025 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral ...

In a recent interview, clips of which have gone viral on social media, Abbasi confirmed that he was diagnosed with nephritis ...

United States real-world studies highlight the importance of controlling lupus nephritis to improve patient prognosis.

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...